Mohamed Bouchahda
About
Mohamed Bouchahda is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Mohamed Bouchahda has authored 43 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 19 papers in Hepatology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mohamed Bouchahda's work include Colorectal Cancer Treatments and Studies (27 papers), Hepatocellular Carcinoma Treatment and Prognosis (19 papers) and Cancer Treatment and Pharmacology (14 papers). Mohamed Bouchahda is often cited by papers focused on Colorectal Cancer Treatments and Studies (27 papers), Hepatocellular Carcinoma Treatment and Prognosis (19 papers) and Cancer Treatment and Pharmacology (14 papers). Mohamed Bouchahda collaborates with scholars based in France, United Kingdom and Belgium. Mohamed Bouchahda's co-authors include Françis Lévi, René Adam, Pasquale F. Innominato, Abdoulaye Karaboué, Sylvie Giacchetti, D. Machover, Denis Castaing, Raphaël Saffroy, C. Focan and Ayhan Ulusakarya and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.
In The Last Decade
Mohamed Bouchahda
43 papers receiving 787 citations
Peers
Mohamed Bouchahda
Dominique Genet France
Abdoulaye Karaboué France
Christian Focan Belgium
Susan B. Brown United States
Kejin Wu China
Susana P. Campos United States
Mingang Ying China
Karen Fagan United States
Roald Ekanger Norway
Fong Wang United States
Citations per year, relative to Mohamed Bouchahda Mohamed Bouchahda (= 1×)
peers
Dominique Genet
Countries citing papers authored by Mohamed Bouchahda
Since
Specialization
Citations
This map shows the geographic impact of Mohamed Bouchahda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Bouchahda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Bouchahda more than expected).
Fields of papers citing papers by Mohamed Bouchahda
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mohamed Bouchahda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Bouchahda. The network helps show where Mohamed Bouchahda may publish in the future.
Co-authorship network of co-authors of Mohamed Bouchahda
This figure shows the co-authorship network connecting the top 25 collaborators of Mohamed Bouchahda. A scholar is included among the top collaborators of Mohamed Bouchahda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamed Bouchahda. Mohamed Bouchahda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bouchahda, Mohamed, Ayhan Ulusakarya, Anne Thirot‐Bidault, et al.. (2023). Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948). BMJ Open. 13(6). e069973–e069973.
2.
Innominato, Pasquale F., Sandra Komarzynski, Robert Dallmann, et al.. (2021). Impact of assessment frequency of patient-reported outcomes: an observational study using an eHealth platform in cancer patients. Supportive Care in Cancer. 29(11). 6167–6170.
3.
Dulong, Sandrine, Qi Huang, Pasquale F. Innominato, et al.. (2021). Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer. Scientific Reports. 11(1). 24015–24015.
4.
Karaboué, Abdoulaye, T. Collon, Ida Pavese, et al.. (2021). Time-dependent efficacy of checkpoint inhibitor nivolumab in metastatic lung cancer patients.. Journal of Clinical Oncology. 39(15_suppl). 9096–9096.
5.
Bouchahda, Mohamed, Raphaël Saffroy, Abdoulaye Karaboué, et al.. (2020). UndetectableRAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients WithRAS-Mutant Metastatic Colorectal Cancer. JCO Precision Oncology. 4(4). 1070–1079.
6.
Bouchahda, Mohamed, et al.. (2020). Improving FOLFIRINOX safety in pancreatic cancer patients through multidimensional remote monitoring and proactive care using a domomedecine mobile platform.. Journal of Clinical Oncology. 38(15_suppl). TPS4673–TPS4673.
7.
Innominato, Pasquale F., Annabelle Ballesta, Qi Huang, et al.. (2020). Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. Cancer Medicine. 9(12). 4148–4159.
8.
Komarzynski, Sandra, Qi Huang, Pasquale F. Innominato, et al.. (2018). Relevance of a Mobile Internet Platform for Capturing Inter- and Intrasubject Variabilities in Circadian Coordination During Daily Routine: Pilot Study. Journal of Medical Internet Research. 20(6). e204–e204.
9.
Lévi, Françis, Abdoulaye Karaboué, Raphaël Saffroy, et al.. (2017). Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). British Journal of Cancer. 117(7). 965–973.
10.
Innominato, Pasquale F., Sandra Komarzynski, Ali Mohammad‐Djafari, et al.. (2016). Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project. Journal of Medical Internet Research. 18(11). e305–e305.
11.
Lévi, Francis, Abdoulaye Karaboué, Marie-Christine Étienne-Grimaldi, et al.. (2016). Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. Clinical Pharmacokinetics. 56(2). 165–177.
12.
Lévi, Françis, Valérie Boige, Mohamed Hebbar, et al.. (2013). Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).. Journal of Clinical Oncology. 31(4_suppl). 466–466.
13.
Bouchahda, Mohamed, Françis Lévi, René Adam, & P. Rougier. (2011). Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. European Journal of Cancer. 47(18). 2681–2690.
14.
Bouchahda, Mohamed, Abdoulaye Karaboué, Raphaël Saffroy, et al.. (2010). Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemotherapy and Pharmacology. 66(3). 605–609.
15.
Lévi, Françis, Abdoulaye Karaboué, Lee Gorden, et al.. (2010). Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemotherapy and Pharmacology. 67(2). 339–348.
16.
Bouchahda, Mohamed, Teresa Macarulla, Françis Lévi, et al.. (2010). Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Medical Oncology. 28(S1). 253–258.
17.
Bouchahda, Mohamed, René Adam, Sylvie Giacchetti, et al.. (2009). Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 115(21). 4990–4999.
18.
Bouchahda, Mohamed, Teresa Macarulla, Jean‐Baptiste Bachet, et al.. (2008). Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Critical Reviews in Oncology/Hematology. 67(3). 255–262.
19.
Adam, R., Dennis A. Wicherts, Robbert J. de Haas, et al.. (2008). Résection hépatique après traitement par agents ciblés de métastases hépatiques initialement non résécables n’ayant pas répondu à une chimiothérapie conventionnelle. Journal de Chirurgie. 145(1). 76–76.
20.
Bachet, Jean‐Baptiste, Pauline Afchain, Christophe Fermanian, et al.. (2007). Cetuximab efficacy in patients treated routinely in university hospitals. Gastroentérologie Clinique et Biologique. 31(11). 941–949.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dominique Genet Breakdown of academic impact, for papers by Abdoulaye Karaboué Breakdown of academic impact, for papers by Christian Focan Breakdown of academic impact, for papers by Susan B. Brown Breakdown of academic impact, for papers by Kejin Wu Breakdown of academic impact, for papers by Susana P. Campos Breakdown of academic impact, for papers by Mingang Ying Breakdown of academic impact, for papers by Karen Fagan Breakdown of academic impact, for papers by Roald Ekanger Breakdown of academic impact, for papers by Fong Wang